文献速递主动脉疾病

ARREST试验:间充质干细胞治疗小腹主动脉瘤的原理与设计

Rationale and Design of the ARREST Trial Investigating Mesenchymal Stem Cells in the Treatment of Small Abdominal Aortic Aneurysm.
PubMed 文献 · Ann Vasc Surg · 2017-09-13

ARREST是一项I期、单中心、双盲、随机对照试验,计划入组36例小腹主动脉瘤(35-45 mm)患者,比较稀释与浓缩间充质干细胞(MSC)输注与安慰剂的差异。主要观察12个月内不良事件、免疫细胞表型、外周细胞因子谱及主动脉周围炎症,并以CT与双功超声定期评估最大横径达5年。目前已入组并治疗4例,预计24个月内完成治疗阶段。

要点

  • MSC输注用于小AAA(35-45 mm)患者,I期试验聚焦安全性。
  • 随访12个月评估不良事件与免疫炎症指标,影像随访最大横径达5年。
  • 结果为后续III期RCT及首个AAA药物干预提供前期数据。

核心结论

  • ARREST试验将评估MSC输注治疗小AAA的安全性,并提供MSC调控AAA相关炎症的初步数据。

研究设计与样本

  • I期、单中心、双盲、随机对照试验,入组36例小AAA(35-45 mm)患者,比较稀释MSC、浓缩MSC与安慰剂。
  • 受试者随访12个月评估不良事件、免疫细胞表型、外周细胞因子谱及主动脉周围炎症;最大横径以CT与双功超声定期评估5年。

主要发现

  • 目前已按方案入组、随机并治疗4例患者。
  • 预计治疗阶段在24个月内结束,长期随访持续进行。

关键数值与推荐

  • 小AAA定义为最大横径35-45 mm。
  • 主要安全性随访期为12个月,影像学横径随访期为5年。

临床怎么用

  • 为小AAA患者提供MSC输注安全性与炎症调控的早期证据,暂不改变现有临床实践。
  • 研究结果将支持设计更大规模III期RCT,探索AAA的首个药物干预。

局限性

  • I期试验样本量小(36例),主要目的是安全性而非疗效。
  • 目前仅4例入组治疗,治疗阶段尚未完成,长期随访仍在进行。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Abdominal aortic aneurysms (AAAs) are a major source of morbidity and mortality despite continuing advances in surgical technique and care. Although the inciting factors for AAA development continue to be elusive, accumulating evidence suggests a significant periaortic inflammatory response leading to degradation and dilation of the aortic wall. Previous human trials have demonstrated safety and efficacy of mesenchymal stem cells (MSCs) in the treatment of inflammation-related pathologies such as rheumatoid arthritis, graft versus host disease, and transplant rejection. Therefore, herein, we describe the Aortic Aneurysm Repression with Mesenchymal Stem Cells (ARREST) trial, a phase I investigation into the safety of MSC infusion for patients with small AAA and the cells' effects on modulation of AAA-related inflammation. METHODS: ARREST is a phase I, single-center, double-blind, randomized controlled trial (RCT) investigating infusion both dilute and concentrated MSCs compared to placebo in 36 small AAA (35-45 mm) patients. Subjects will be followed by study personnel for 12 months to ascertain incidence of adverse events, immune cell phenotype expression, peripheral cytokine profile, and periaortic inflammation. Maximum transverse aortic diameter will be assessed regularly for 5 years by a combination of computed tomography and duplex sonography. RESULTS: Four patients have thus far been enrolled, randomized, and treated per protocol. We anticipate the conclusion of the treatment phase within the next 24 months with ongoing long-term follow-up. CONCLUSIONS: ARREST will be pivotal in assessing the safety of MSC infusion and provide preliminary data on the ability of MSCs to favorably modulate the pathogenic AAA host immune response. The data gleaned from this phase I trial will provide the groundwork for a larger, phase III RCT which may provide the first pharmaceutical intervention for AAA.

来源:Ann Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Wang SK, Green LA, Gutwein AR, et al. Rationale and Design of the ARREST Trial Investigating Mesenchymal Stem Cells in the Treatment of Small Abdominal Aortic Aneurysm. Ann Vasc Surg. 2017. PMID: 28916304. doi:10.1016/j.avsg.2017.08.044

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。